Heidelberg Pharma GmbH is a pharmaceutical company with a dual business model: (A) Providing preclinical drug development services in general with a special focus on the development of ADCs. Heidelberg Pharma has ample experience in providing antibody-drug conjugate related services to its clients. (B) Development of novel therapeutics in oncology based on its own proprietary 2nd generation ADC technology based on a novel toxin.
ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company’s lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancer and other solid tumors. A number of major healthcare companies have licensed limited rights to use ImmunoGen’s ADC technology to develop anticancer therapies; it is used in Roche’s marketed product, Kadcyla.
At Levena BioPharma, we interface complex synthetic chemistry with antibody research providing our clients with the latest technologies and comprehensive services to advance ADC projects from discovery to IND. Our ADC platform encompasses: ADC screening tools; bioactive molecules (toxins) for research and in cGMP grade; optimized linker-toxins; conjugation services; ADC toxicity screening; and ADC optimization & processing.
Seattle Genetics improves the lives of people with cancer through innovative and empowered antibody-based therapies. ADCETRIS(r) (brentuximab vedotin), the company’s lead product, is the first in a new class of ADCs for relapsed classical Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. Seattle Genetics has a robust pipeline of innovative therapies for blood-related cancers and solid tumors, including vadastuximab talirine, an ADC in a phase 3 trial for acute myeloid leukemia.
ADC Bio is an innovative biotechnology company developing new process technology to speed, simplify and significantly lower the production costs of ADCs. The company are specialists in state-of-the-art bio-conjugation techniques and cytotoxin drug-linker synthesis, assisting drug developers to deliver their next generation ADCs. Our proprietary ‘Lock-Release’ technology aims to become a new paradigm in the way ADCs are developed and manufactured by providing fast, simple and robust conjugation processes. www.adcbio.com
Multitude Therapeutics (MTX) is a preclinical-stage business unit created by Abmart to leverage its unparalleled target and antibody discovery capability for cancer immunotherapy.MTX focuses on developing novel antibody-drug conjugates (ADC) and immuno-oncology (I/O) (T cells and macrophages) based antibody therapeutics for solid and… Read more
Abzena provides technology solutions enabling development of better biopharmaceuticals through its subsidiaries PolyTherics and Antitope. PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimization of the therapeutic properties of biopharmaceuticals. Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.
Ajinomoto Althea, Inc. is a fully integrated contract development and manufacturing organization (CDMO) committed to the success of our clients for process development, drug substance manufacturing and drug product manufacturing. In a single location, Althea has the capacity to support early-stage clinical requirements through commercial manufacturing. Althea is a leading expert in executing drug formulation and aseptic fill finish for vials and syringes. We pride ourselves on being the manufacturing partner that delivers the relentless dedication and support our clients need.
BioPharma Solutions, a business unit of Baxter, partners with pharmaceutical companies to support their commercialization objectives by providing scientific expertise, sterile contract manufacturing solutions, parenteral delivery systems, and customized support services needed to meet the unique challenges that parenteral products face.
BlinkBio is developing a novel Tunable Drug Conjugates (TDCs) platform for the treatment of oncology and other diseases. Using proprietary SiLinkers and Payload Cassettes, TDCs employ a differentiated rapid payload release/rapid systemic clearance approach designed to drive high payload concentrations within target cells while minimizing toxicities to patients. Our business strategy is to advance selected TDCs through clinical development while partnering with major pharmaceutical and biotech companies to broaden the platform’s utility and application.